Eloralintide: Reading a Weight-Loss Trial
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Eloralintide targets amylin receptors, part of the biology of appetite. Its clinical evidence is best understood by looking at the actual trial. A 2025 randomized, placebo-controlled phase two study followed 263 adults with obesity or overweight and a related condition, without type two diabetes. Over 48 weeks, treated groups lost more weight than the placebo group. Nausea and fatigue were among the most common reported adverse events. Those findings describe selected participants, a defined formulation, and a limited follow-up period. They cannot establish lifelong safety or validate unrelated products bearing the same name.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Billings et al. (2025): Eloralintide, a selective amylin receptor agonist for the treatment of obesity
https://pubmed.ncbi.nlm.nih.gov/41207310/
Primary human randomized phase 2 trial

EVIDENCE LIMITATIONS
Phase 2 results are not lifelong safety evidence.
Participants without type 2 diabetes do not represent every clinical population.
A sponsor-manufactured study formulation does not establish equivalence to commercial research materials.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Eloralintide: Reading a Weight-Loss Trial